Tests milkshake diet with biologic medicines in children with Crohn's disease
Tests milkshake nutrition alongside biologics in children with active Crohn's disease.
Plain-language title generated from the registry record
Registry title: Biologics and Paediatric Enteral Nutrition in Crohn's Disease Study
Key facts
- Where
- Aberdeen, Crosshouse, Dundee, Edinburgh, Glasgow, and Wishaw, United KingdomSee the 6 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 6 and 18 years old?
Source: NCT07522528, who can take part
Where in United Kingdom
- The Royal Aberdeen Children's HospitalAberdeen, United KingdomNot yet recruiting
- University Hospital CrosshouseCrosshouse, United KingdomNot yet recruiting
- Ninewells HospitalDundee, United KingdomNot yet recruiting
- Royal Hospital for Children & Young PeopleEdinburgh, United KingdomTaking people
- Royal Hospital for ChildrenGlasgow, United KingdomTaking people
- University Hospital WishawWishaw, United KingdomNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Glasgow
- Trial code
- NCT07522528
- Record updated
- 13 April 2026
- Original description
Crohn's disease (CD) is a chronic, incurable condition associated with gut inflammation. Two important treatments currently used to manage CD are special drug injections (biologics) or a liquid-only diet using specialised milkshakes. However, treatment with biologics is only successful in approximately 55-60%. The liquid-only diet also has a better safety and effectiveness profile than traditional treatments like steroids. However, gut inflammation often returns not long after the normal diet is re-introduced, and it is difficult for patients to stick to as their sole source of nutrition for 6-8 weeks.Read full original descriptionShow less
Biologics and Paediatric Enteral Nutrition in Crohn's Disease Study (BIOPIC-Kids): Combining Enteral Nutrition With Biologics to Optimise Induction and Maintenance Therapy for Children With Active Crohn's Disease
Crohn's disease (CD) is a chronic, incurable condition associated with gut inflammation. Two important treatments currently used to manage CD are special drug injections (biologics) or a liquid-only diet using specialised milkshakes. However, treatment with biologics is only successful in approximately 55-60%. The liquid-only diet also has a better safety and effectiveness profile than traditional treatments like steroids. However, gut inflammation often returns not long after the normal diet is re-introduced, and it is difficult for patients to stick to as their sole source of nutrition for 6-8 weeks.
The BIOPIC-Kids study aims to investigate whether replacing the normal diet with specialised milkshakes for 6 weeks improves response to treatment and maintenance of remission with biologics in children and young adults with CD. To achieve this, children and young adults (aged 6-18 years) with active CD commencing biologics as standard of care treatment will be randomly allocated to follow their normal diet OR replace varying amounts of their normal diet with specialised milkshakes for 6 weeks. Participants not wanting to be randomised can choose the group of their preference. Patients starting a liquid-only diet OR biologics alongside a liquid-only diet as standard of care treatment will also be recruited to compare different treatment outcomes.
Inclusion: Eligible participants to the RCT are children or young adults (aged 6 to 18 years old) who have active CD (defined as a weighted paediatric Crohn's disease Activity Index score (wPCDAI) ≥ 12.5 or a Faecal Calprotectin level >250 mg/kg and who have a clinical indication to initiate standard of care induction treatment with TNFα inhibitors (infliximab or adalimumab); Eligible participants to the observational cohorts are children or young adults (aged 6 to 18 years old) who have active CD (defined as a weighted paediatric Crohn's disease Activity Index score (wPCDAI) ≥ 12.5 or a Faecal Calprotectin level >250 mg/kg and who are due to initiate standard of care induction treatment with EEN therapy alongside TNFα inhibitors (infliximab or adalimumab) or standard of care induction treatment with EEN therapy without TNFα inhibitors (infliximab or adalimumab).
Exclusion: Patients currently receiving oral or intravenous steroids at a dosage >20mg/day prednisolone or >9mg/day budesonide; Patients who start another induction therapy (e.g., high dosage of steroids) or change the dose of background immunomodulator (azathioprine, mercaptopurine, methotrexate) within the past 4 weeks; Current enrolment in other studies of an investigational product or dietary intervention; Presence of stoma or of short bowel syndrome; Patients tested positive for blood-borne viruses such as HIV and Hepatitis B and C; Patients with untreated tuberculosis (latent or active); Food allergies, which do not permit participation in the study (e.g., cow's milk allergy); Inability to provide consent to participate in the study (i.e., this applies to young adults (aged 16-18 years) who are old enough but unable to provide consent and carers (of children aged 6-15 years old) who are unable to provide consent on behalf of their child); CD with a major fistulising or symptomatic fibrotic stricturing phenotype; Patients with comorbid anorexia nervosa; Any clinical contraindication to use of exclusive enteral nutrition or partial enteral nutrition; Pregnant and/or breastfeeding individuals.